[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639718":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":21,"responsibleParty":40,"collaborators":10,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":10,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"University Medical Centre Ljubljana","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Takotsubo patients with preserved OR mildly reduced\u002Freduced LVEF at acute event.",null,"Takotsubo patients divided in subgroups based on preserved or mildly reduced\u002Freduced LVEF at acute event.",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Mark Jovanović, MD","CONTACT","+38640977307","mark.jovanovic@kclj.si",{"name":19,"role":15,"phone":10,"phoneExt":10,"email":20},"Principal Investigator","gregor.poglajen@kclj.si",[22],{"facility":23,"status":24,"city":25,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Advanced Heart Failure and Transplantation Program, Department of Cardiology, UMC Ljubljana, Slovenia","RECRUITING","Ljubljana","1000","Slovenia","SI",{"type":30,"coordinates":31},"Point",[32,33],14.50513,46.05108,{"lat":33,"lon":32},[36],{"name":37,"role":15,"phone":38,"phoneExt":10,"email":39},"Jovanović, Prof. Poglajen","Jovanović: +38640977307","mark.jovanovic@kclj.si ; gregor.poglajen@kclj.si",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Gregor Poglajen","Associate Professor","100639718","the-role-of-cd34-stem-cells-in-the-pathogenesis-of-takotsubo-syndrome-100639718",false,"NCT07604467","The Role of CD34+ Stem Cells in the Pathogenesis of Takotsubo Syndrome","Effects of CD34+ Stem Cells on Left Ventricular Dysfunction Among Patients With Takotsubo Syndrome","STRESS","Inclusion Criteria:\n\n* Minimum age 18 years\n* Established TTS per InterTak registry criteria\n* Signed consent form\n\nExclusion Criteria:\n\n* Patients under the age of 18 years\n* Ischemic heart disease with at least one complete total occlusion\n* Other concurrent cardiomyopathies\n* Active infectious myocarditis\n* obstructive coronary artery disease\n* Previous hospital stay due to acute coronary syndrome (myocardial infarction) in the last 6 months before TTS acute event\n* Previous interventional coronary artery procedure in the last 6 months before TTS acute event\n* Significant valvular heart disease\n* Significant peripheral artery occlusive disease\n* Active or remitted hematologic malignancy\n* Patients receiving immunosuppressive therapy\n* Significant comorbiditeis affecting patients survival (malignancy)\n* Failure to obtain freely given, informed consent form.","ALL","18 Years",{"count":55,"type":56},40,"ESTIMATED","OBSERVATIONAL","The underlying mechanisms of microvascular dysfunction in Takotsubo cardiomyopathy remain incompletely understood. As CD34+ cells are essential to coronary microvascular homeostasis we will investigate the potential association between CD34+ cell count and changes in left ventricular function in patients with Takotsubo cardiomyopathy at baseline and 6-month follow-up.",[60,61,62,63,64],"Tako Tsubo Cardiomyopathy","Microvascular Dysfunction","CD34+ Stem Cells","Heart Failure","Cardiac Contractility Recovery",[66,67,68,69,70],"Takotsubo syndrome","CD34+ stem cells","heart failure","microvascular dysfunction","cardiac contractility recovery","2026-05-17",{"date":73,"type":74},"2026-05-22","ACTUAL",{"date":76,"type":74},"2021-09-06",{"date":78,"type":56},"2026-12-31",{"name":5,"class":6},1]